IPP Bureau
LANXESS showcases extensive portfolio for the cosmetics industry at in-cosmetics Global
By IPP Bureau - April 07, 2024
Highly effective preservation solutions ensuring the safety and protection of personal care products
.jpg "Cipla Patalganga facility gets 6 USFDA observations")
Cipla Patalganga facility gets 6 USFDA observations
By IPP Bureau - April 07, 2024
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma
By IPP Bureau - April 06, 2024
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
By IPP Bureau - April 06, 2024
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial
By IPP Bureau - April 06, 2024
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData
By IPP Bureau - April 06, 2024
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Aster DM Healthcare concludes separation of India and GCC businesses
By IPP Bureau - April 05, 2024
The company plans to add 1700 beds by FY27 through the organic route
Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer
By IPP Bureau - April 05, 2024
Dabur India expects mid-single digit revenue growth in Q4
By IPP Bureau - April 05, 2024
International Business is expected to register double-digit growth in constant currency terms
Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
By IPP Bureau - April 05, 2024
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Abbott receives FDA approval for TriClip
By IPP Bureau - April 04, 2024
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Aurigene introduces AI/ML assisted drug discovery platform
By IPP Bureau - April 04, 2024
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Evonik unveils latest global trial results MetAMINO
By IPP Bureau - April 04, 2024
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
